Multiple sclerosis, or MS, is a devastating inflammatory disease that often progresses and causes severe neurological, physical, and cognitive effects. Fingolimod is a sphingosine 1-phosphate receptor modulator for the treatment of relapsing-remitting multiple sclerosis. It was developed by Novartis and initially approved by the FDA in 2010. Fingolimod was also studied for the treatment of COVID-19, the disease caused by infection with the SARS-CoV-2 virus. It is grouped under the following drug class(es): Immunosuppressants. Its therapeutic use is listed as multiple sclerosis agents. The directory classifies it as a commercial API with a synthetic source/manufacturing origin. Other names for this substance include Gilenya and fingolimodum. Its PubChem CID is 107970.
Fingolimod
| CAS No | 162359-55-9 |
|---|---|
| Molecular Formula | C19H33NO2 |
| Molecular Weight | 307.5 g/mol |
| Synonyms | 2-amino-2-[2-(4-octylphenyl)ethyl]propane-1,3-diol |
Zoho Contact Form
"*" indicates required fields
Frequently Asked Questions
Multiple sclerosis, or MS, is a devastating inflammatory disease that often progresses and causes severe neurological, physical, and cognitive effects. Fingolimod is a sphingosine 1-phosphate receptor modulator for the treatment of relapsing-remitting multiple sclerosis.
The listed CAS number is 162359-55-9.
The listed molecular formula is C19H33NO2.
The listed molecular weight is 307.5 g/mol.
2-amino-2-[2-(4-octylphenyl)ethyl]propane-1,3-diol.
The source lists Gilenya and fingolimodum.